233 related articles for article (PubMed ID: 35201310)
1. Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
Yunusa I; Gagne JJ; Yoshida K; Bykov K
JAMA Netw Open; 2022 Feb; 5(2):e220194. PubMed ID: 35201310
[TBL] [Abstract][Full Text] [Related]
2. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.
Donneyong MM; Bykov K; Bosco-Levy P; Dong YH; Levin R; Gagne JJ
BMJ; 2016 Sep; 354():i5014. PubMed ID: 27694571
[TBL] [Abstract][Full Text] [Related]
3. [Serotoninergic antidepressants and opiate analgesics: a sometimes-painful association. A case report].
Reich M; Lefebvre-Kuntz D
Encephale; 2010 Jun; 36 Suppl 2():D119-23. PubMed ID: 20513454
[TBL] [Abstract][Full Text] [Related]
4. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
[TBL] [Abstract][Full Text] [Related]
5. Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.
Oskotsky T; Maric I; Tang A; Oskotsky B; Wong RJ; Aghaeepour N; Sirota M; Stevenson DK
JAMA Netw Open; 2021 Nov; 4(11):e2133090. PubMed ID: 34779847
[TBL] [Abstract][Full Text] [Related]
6. Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors.
Bali V; Chatterjee S; Carnahan RM; Chen H; Johnson ML; Aparasu RR
Psychiatr Serv; 2015 Dec; 66(12):1333-40. PubMed ID: 26234334
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors: A Multidatabase Observational Cohort Study.
Dong YH; Bykov K; Choudhry NK; Donneyong MM; Huybrechts KF; Levin R; Schneeweiss S; Gagne JJ
J Clin Psychopharmacol; 2017 Apr; 37(2):200-209. PubMed ID: 28129313
[TBL] [Abstract][Full Text] [Related]
8. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
Assimon MM; Brookhart MA; Flythe JE
J Am Soc Nephrol; 2019 Apr; 30(4):611-623. PubMed ID: 30885935
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
Bogetto F; Bellino S; Revello RB; Patria L
CNS Drugs; 2002; 16(4):273-83. PubMed ID: 11945110
[TBL] [Abstract][Full Text] [Related]
10. Comparative Risk of Opioid Overdose With Concomitant Use of Prescription Opioids and Skeletal Muscle Relaxants.
Khan NF; Bykov K; Barnett ML; Glynn RJ; Vine SM; Gagne JJ
Neurology; 2022 Sep; 99(13):e1432-e1442. PubMed ID: 35835561
[TBL] [Abstract][Full Text] [Related]
11. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
[TBL] [Abstract][Full Text] [Related]
12. Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents.
Sun JW; Hernández-Díaz S; Haneuse S; Bourgeois FT; Vine SM; Olfson M; Bateman BT; Huybrechts KF
JAMA Psychiatry; 2021 Jan; 78(1):91-100. PubMed ID: 32876659
[TBL] [Abstract][Full Text] [Related]
13. Drug overdose risk with benzodiazepine treatment in young adults: Comparative analysis in privately and publicly insured individuals.
Bushnell GA; Rynn MA; Gerhard T; Keyes KM; Hasin DS; Cerdá M; Nyandege A; Olfson M
Addiction; 2024 Feb; 119(2):356-368. PubMed ID: 37816665
[TBL] [Abstract][Full Text] [Related]
14. Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone.
Weiner SG; Hendricks MA; El Ibrahimi S; Ritter GA; Hallvik SE; Hildebran C; Weiss RD; Boyer EW; Flores DP; Nelson LS; Kreiner PW; Fischer MA
PLoS One; 2022; 17(4):e0266561. PubMed ID: 35381052
[TBL] [Abstract][Full Text] [Related]
15. Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression.
Desai R; Park H; Brown JD; Mohandas R; Smith SM
Pharmacotherapy; 2022 Jun; 42(6):472-482. PubMed ID: 35478186
[TBL] [Abstract][Full Text] [Related]
16. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
[TBL] [Abstract][Full Text] [Related]
17. Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine.
Bali V; Chatterjee S; Johnson ML; Chen H; Carnahan RM; Aparasu RR
Pharmacotherapy; 2017 Mar; 37(3):287-296. PubMed ID: 28079266
[TBL] [Abstract][Full Text] [Related]
18. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
[TBL] [Abstract][Full Text] [Related]
19. Serotonin syndrome induced by fluvoxamine and oxycodone.
Karunatilake H; Buckley NA
Ann Pharmacother; 2006 Jan; 40(1):155-7. PubMed ID: 16368927
[TBL] [Abstract][Full Text] [Related]
20. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
Schneeweiss S; Patrick AR; Solomon DH; Mehta J; Dormuth C; Miller M; Lee JC; Wang PS
Arch Gen Psychiatry; 2010 May; 67(5):497-506. PubMed ID: 20439831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
